Iovance Biotherapeutics (NASDAQ:IOVA) Shares Down 5.9% on Analyst Downgrade

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA - Get Free Report) was down 5.9% during trading on Tuesday after Barclays lowered their price target on the stock from $22.00 to $5.00. Barclays currently has an overweight rating on the stock. Iovance Biotherapeutics traded as low as $3.20 and last traded at $3.21. Approximately 3,959,691 shares were traded during trading, a decline of 60% from the average daily volume of 9,785,074 shares. The stock had previously closed at $3.41.

• The Top 5 Analysts Ranked by MarketBeat and Stocks They Cover

Other analysts have also recently issued reports about the stock. Robert W. Baird decreased their price objective on shares of Iovance Biotherapeutics from $24.00 to $20.00 and set an "outperform" rating for the company in a research note on Friday, February 28th. The Goldman Sachs Group lowered their price target on shares of Iovance Biotherapeutics from $22.00 to $19.00 and set a "buy" rating on the stock in a report on Monday, March 3rd. Piper Sandler decreased their price objective on Iovance Biotherapeutics from $7.50 to $6.00 and set a "neutral" rating for the company in a report on Friday, February 28th. Truist Financial reduced their price target on Iovance Biotherapeutics from $25.00 to $15.00 and set a "buy" rating for the company in a research report on Monday, March 3rd. Finally, HC Wainwright reaffirmed a "buy" rating and set a $32.00 price objective on shares of Iovance Biotherapeutics in a research note on Friday, February 28th. One research analyst has rated the stock with a sell rating, one has given a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat.com, Iovance Biotherapeutics has an average rating of "Moderate Buy" and a consensus price target of $18.56.

Get Our Latest Research Report on Iovance Biotherapeutics

Institutional Investors Weigh In On Iovance Biotherapeutics

• How to Trade Stocks Online the Right Way

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. AlphaQuest LLC lifted its stake in Iovance Biotherapeutics by 63.6% in the 4th quarter. AlphaQuest LLC now owns 4,613 shares of the biotechnology company's stock worth $34,000 after purchasing an additional 1,794 shares in the last quarter. SBI Securities Co. Ltd. purchased a new stake in Iovance Biotherapeutics in the 4th quarter valued at $36,000. GF Fund Management CO. LTD. purchased a new position in shares of Iovance Biotherapeutics during the 4th quarter worth $47,000. One68 Global Capital LLC acquired a new position in shares of Iovance Biotherapeutics during the 4th quarter valued at about $74,000. Finally, Quarry LP purchased a new stake in shares of Iovance Biotherapeutics in the fourth quarter valued at about $74,000. Institutional investors and hedge funds own 77.03% of the company's stock.

Iovance Biotherapeutics Stock Performance

The firm's 50 day moving average price is $4.15 and its two-hundred day moving average price is $6.94. The firm has a market cap of $1.05 billion, a PE ratio of -2.15 and a beta of 1.05.

• Iovance Biotherapeutics Spikes on Melanoma BLA FDA Application

Iovance Biotherapeutics (NASDAQ:IOVA - Get Free Report) last announced its quarterly earnings results on Thursday, February 27th. The biotechnology company reported ($0.26) EPS for the quarter, meeting the consensus estimate of ($0.26). The business had revenue of $73.69 million for the quarter, compared to analyst estimates of $72.17 million. Iovance Biotherapeutics had a negative return on equity of 58.43% and a negative net margin of 451.25%. On average, analysts forecast that Iovance Biotherapeutics, Inc. will post -1.24 earnings per share for the current year.

About Iovance Biotherapeutics

Iovance Biotherapeutics, Inc, a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma.

Read More

• Five stocks we like better than Iovance Biotherapeutics
• How to Calculate Stock Profit
• Beware of BigBear.ai: Insiders Are Selling—Should You?
• Stock Dividend Cuts Happen Are You Ready?
• CrowdStrike Stock is a Buy as Cyberthreat Environment Expands
• What is a Dividend King?
• Congress! Who Traded What During the Tariff-Induced Meltdown

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Iovance Biotherapeutics Right Now?

Before you consider Iovance Biotherapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Iovance Biotherapeutics wasn't on the list.

While Iovance Biotherapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here